2070015-26-6|SRT3025 HCl|5-(3-methoxypropyl)-2-phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide hydrochloride|-范德生物科技公司

SRT3025 HCl

NMR下载 COA and HPLC MSDS下载
names：
5-(3-methoxypropyl)-2-phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide hydrochloride
CAS号：
2070015-26-6
MDL Number：
MF(分子式)： C31H32ClN5O2S2 MW(分子量)： 606.2
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	5-(3-methoxypropyl)-2-phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide hydrochloride
英文别名	SRT3025 HCl; SRT3025 hydrochloride; SRT3025; SRT-3025; SRT 3025;
CAS号	2070015-26-6
SMILES	C1C=C(C2SC(CCCOC)=C(C(NC3C=CC=CC=3C3=NC4=C(N=CC(=C4)CN4CCCC4)S3)=O)N=2)C=CC=1.Cl
Inchi	InChI=1S/C31H31N5O2S2.ClH/c1-38-17-9-14-26-27(35-29(39-26)22-10-3-2-4-11-22)28(37)33-24-13-6-5-12-23(24)30-34-25-18-21(19-32-31(25)40-30)20-36-15-7-8-16-36;/h2-6,10-13,18-19H,7-9,14-17,20H2,1H3,(H,33,37);1H
InchiKey	LGRBDTOIPNDWMN-UHFFFAOYSA-N
分子式 Formula	C31H32ClN5O2S2
分子量 Molecular Weight	606.2
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	SRT3025 HCl(CAS:2070015-26-6 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	SRT3025 is a potent and selective Sirt1 activator. SRT3025 Inhibits RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. SRT3025 down-regulates sclerostin and rescues ovariectomy-induced bone loss and biomechanical deterioration in female mice. SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Zhang Y, Thai K, Jin T, Woo M, Gilbert RE. SIRT1 activation attenuates α cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice. Sci Rep. 2018 Sep 18;8(1):13972. doi: 10.1038/s41598-018-32351-z. PubMed PMID: 30228292; PubMed Central PMCID: PMC6143559.

[2]Zhang Y, Connelly KA, Thai K, Wu X, Kapus A, Kepecs D, Gilbert RE. Sirtuin 1 Activation Reduces Transforming Growth Factor-β1-Induced Fibrogenesis and Affords Organ Protection in a Model of Progressive, Experimental Kidney and Associated Cardiac Disease. Am J Pathol. 2017 Jan;187(1):80-90. doi: 10.1016/j.ajpath.2016.09.016. PubMed PMID: 27993241.

[3] Opal SM, Ellis JL, Suri V, Freudenberg JM, Vlasuk GP, Li Y, Chahin AB, Palardy JE, Parejo N, Yamamoto M, Chahin A, Kessimian N. PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS. Shock. 2016 Apr;45(4):411-8. doi: 10.1097/SHK.0000000000000528. PubMed PMID: 26974318.

[4] El-Haj M, Gurt I, Cohen-Kfir E, Dixit V, Artsi H, Kandel L, Yakubovsky O, Safran O, Dresner-Pollak R. Reduced Sirtuin1 expression at the femoral neck in women who sustained an osteoporotic hip fracture. Osteoporos Int. 2016 Jul;27(7):2373-2378. doi: 10.1007/s00198-016-3536-4. Epub 2016 Feb 22. PubMed PMID: 26902093.

[5] Chini CC, Espindola-Netto JM, Mondal G, Guerrico AM, Nin V, Escande C, Sola-Penna M, Zhang JS, Billadeau DD, Chini EN. SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Clin Cancer Res. 2016 May 15;22(10):2496-507. doi: 10.1158/1078-0432.CCR-15-1760. Epub 2015 Dec 11. PubMed PMID: 26655844; PubMed Central PMCID: PMC4867252.

6: Kim HN, Han L, Iyer S, de Cabo R, Zhao H, O'Brien CA, Manolagas SC, Almeida M. Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs. Mol Endocrinol. 2015 Oct;29(10):1498-509. doi: 10.1210/me.2015-1133. Epub 2015 Aug 19. PubMed PMID: 26287518; PubMed Central PMCID: PMC4588729.7: Gurt I, Artsi H, Cohen-Kfir E, Hamdani G, Ben-Shalom G, Feinstein B, El-Haj M, Dresner-Pollak R. The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391. doi: 10.1371/journal.pone.0134391. eCollection 2015. PubMed PMID: 26226624; PubMed Central PMCID: PMC4520518.8: Zhang QS, Deater M, Schubert K, Marquez-Loza L, Pelz C, Sinclair DA, Grompe M. The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice. Stem Cell Res. 2015 Jul;15(1):130-40. doi: 10.1016/j.scr.2015.05.007. Epub 2015 May 22. PubMed PMID: 26046330; PubMed Central PMCID: PMC4516677.9: Gilbert RE, Thai K, Advani SL, Cummins CL, Kepecs DM, Schroer SA, Woo M, Zhang Y. SIRT1 activation ameliorates hyperglycaemia by inducing a torpor-like state in an obese mouse model of type 2 diabetes. Diabetologia. 2015 Apr;58(4):819-27. doi: 10.1007/s00125-014-3485-4. Epub 2015 Jan 7. PubMed PMID: 25563725.10: Li Y, Shen G, Yu C, Li G, Shen J, Gong J, Xu Y. Angiotensin II induces mitochondrial oxidative stress and mtDNA damage in osteoblasts by inhibiting SIRT1–FoxO3a–MnSOD pathway. Biochem Biophys Res Commun. 2014 Dec 5;455(1-2):113-8. PubMed PMID: 25450701.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开